alogliptin vs dolutegravir

According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.

Side-by-side comparison of alogliptin and dolutegravir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.

minor Known Drug Interaction

( 7 ) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin on lactate metabolism.

Drug Class
alogliptin DPP-4 Inhibitor
dolutegravir Integrase Strand Transfer Inhibitor
Type
alogliptin Prescription
dolutegravir Prescription
Summary
alogliptin

No summary available.

dolutegravir

TRIUMEQ is a drug that contains three medicines in one pill: dolutegravir, abacavir, and lamivudine. It is used to treat HIV-1 infection in adults and children.

What It Treats
alogliptin

Information not available.

dolutegravir

TRIUMEQ treats HIV-1, the virus that causes AIDS. It helps to lower the amount of virus in your body. This medication can help your body fight infection and can improve your health.

How It Works
alogliptin

Information not available.

dolutegravir

TRIUMEQ contains three drugs that each work differently to stop HIV from multiplying. Dolutegravir is an integrase strand transfer inhibitor (INSTI). Abacavir and lamivudine are nucleoside analogue reverse transcriptase inhibitors.

Common Side Effects
alogliptin
  • Upper respiratory tract infection
  • Common cold
  • Diarrhea
  • High blood pressure
  • Headache
dolutegravir
  • Trouble sleeping (insomnia)
  • Headache
  • Feeling tired
FAERS Reports
alogliptin
  • Diarrhoea 134
  • Nausea 124
  • Vomiting 110
  • Acute Kidney Injury 101
  • Pemphigoid 101
dolutegravir
  • Pain 1,425
  • Anxiety 1,051
  • Emotional Distress 1,048
  • Anhedonia 942
  • Chronic Kidney Disease 701
Serious Warnings
alogliptin

No specific warnings noted.

dolutegravir

TRIUMEQ can cause serious allergic reactions. If you have a gene called HLA-B*5701, you are more likely to have an allergic reaction. You should be tested for this gene before taking TRIUMEQ. Symptoms can include fever, rash, nausea, vomiting, diarrhea, or stomach pain. Some people can also experience liver problems or a heart attack.

Pregnancy
alogliptin

No pregnancy information available.

dolutegravir

Tell your doctor if you are pregnant or plan to become pregnant. There is a pregnancy registry to monitor outcomes in people who take TRIUMEQ during pregnancy. Talk to your doctor about the risks and benefits of taking TRIUMEQ during pregnancy.

Also Compare, Nearby Drugs

How to Read This alogliptin vs dolutegravir Comparison

alogliptin is classified in the DPP-4 Inhibitor drug class, while dolutegravir sits within the Integrase Strand Transfer Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.

Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alogliptin has 570 submissions while dolutegravir has 5,167. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to dolutegravir can slow down how quickly the body removes metformin. this can cause metformin to build up in the blood, increasing the risk of side effects.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.

A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for alogliptin or dolutegravir.

Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.